Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. 

Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.  

We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. 

  • Therapy areas: Diabetes, ​Obesity, Rare Disease, Cardiovascular & Emerging Therapy Areas​
  • Globally serving more than 45.2 million people living with serious chronic diseases​

    Learn more about our focus disease areas

 

  • Number of employees: 78.400​ 
  • Number of employees in US: 33.700
  • Number of employees in DK: 11.200
  • Affiliates in 80 countries​ 

 

  • Strategic production sites in Belgium, Brazil, China, Denmark, France, Italy and the US​
  • Announced Production Expansion Investments: 65 bn DKK in 2025 (compared to 45 bn in 2024)

    Our medicines
     

 

  • Corporate income tax in Denmark in 2024: 21.6 bn DKK (2023: 14.7 bn DKK​)
  • Employee income tax in Denmark in 2024: 10.3 bn​ DKK (2023: 7.8 bn DKK)